Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05295407 · ClinicalTrials.gov registry record
Performance of Inherited Risk Assessment for Predicting Prostate Cancer From Prostate Biopsy
A clinical trial of Prostate Cancer, sponsored by Endeavor Health.
- Recruiting
- Registry status
- 1,000
- Enrollment target
- 1
- Study location
NCT05295407 is a study of Prostate Cancer that is actively recruiting participants, run by Endeavor Health. The registered enrollment target is 1,000 participants, above the 607-participant average among 735 other Prostate Cancer trials with a reported enrollment target (65% higher). The trial reports 1 study location across 1 state.
The verdict
NCT05295407, a study of Prostate Cancer, is actively recruiting participants, sponsored by Endeavor Health.
- RECRUITING
- Registry status
- 1,000 participants
- Enrollment target
- 1
- Study location
Study Summary
Condition: Prostate cancer Intervention: Biopsy and inherited risk assessment
Conditions Studied
Interventions
- GENETIC Genetic Assessment
Study Locations (1)
Illinois
- NorthShore University HealthSystem - Evanston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2021-12-13 |
| Est. Completion | 2027-12-13 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05295407
The ClinicalTrials.gov registry entry for NCT05295407 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 607-participant average among 735 other Prostate Cancer trials with a reported enrollment target (65% higher). The listed sponsor is Endeavor Health, which has 94 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which Genetic Assessment is the first listed.
NCT05295407 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT05295407 about?
NCT05295407 is a clinical study titled "Performance of Inherited Risk Assessment for Predicting Prostate Cancer From Prostate Biopsy". Condition: Prostate cancer Intervention: Biopsy and inherited risk assessment
What is the current status of trial NCT05295407?
This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2021-12-13. Estimated completion is 2027-12-13.
What conditions does trial NCT05295407 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT05295407?
The interventions under investigation include: Genetic Assessment (GENETIC).
Who is sponsoring clinical trial NCT05295407?
This trial is sponsored by Endeavor Health, which has 94 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05295407 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Improving Health Literacy in African-American Prostate Cancer Patients
RECRUITING · NA
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.